// STATE LEGISLATION TRACKER

New York A10004: CAPITAL PROJECTS BUDGET

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: New York
Bill: A10004
Session: 2025-2026
Filed: 2026-01-21
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

This is New York's capital projects budget bill, which funds state construction, infrastructure, facilities, and other capital spending. Based on the title, summary, and available status information, it does not appear to directly change peptide access, prescribing rules, telehealth, clinician scope, compounding, controlled substances, or prescription monitoring.

Key Points

No direct peptide prescribing change is apparent from the bill summary
No apparent change to 503A or 503B compounding rules
No apparent telehealth expansion or restriction for peptide care
No apparent NP or naturopathic scope-of-practice change
No apparent controlled-substance or PDMP change

What to Watch For

Note This is a broad capital budget, so any health impact would likely be indirect through funded facilities or programs.

Note The latest action references line-veto memos, meaning some budget items may have been removed after passage.

Note Peptide users and clinicians should watch separate health, pharmacy, and professional-scope bills for direct changes.

Where the Bill Stands

The bill passed both chambers, was signed as Chapter 54 on June 9, 2026, and then had line-veto memo actions recorded.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws